- Home
- TERN vs MLTX Comparison
TERN vs MLTX Comparison
Compare TERN & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TERN
- MLTX
- Stock Information
- Founded
- TERN 2017
- MLTX 2021
- Country
- TERN United States
- MLTX Switzerland
- Employees
- TERN N/A
- MLTX 100
- Industry
- TERN Biotechnology: Pharmaceutical Preparations
- MLTX Biotechnology: Pharmaceutical Preparations
- Sector
- TERN Health Care
- MLTX Health Care
- Exchange
- TERN Nasdaq
- MLTX Nasdaq
- Market Cap
- TERN 710.6M
- MLTX 904.7M
- IPO Year
- TERN 2021
- MLTX N/A
- Fundamental
- Price
- TERN $20.33
- MLTX $12.63
- Analyst Decision
- TERN Buy
- MLTX Buy
- Analyst Count
- TERN 11
- MLTX 9
- Target Price
- TERN $21.19
- MLTX $36.78
- AVG Volume (30 Days)
- TERN 4.5M
- MLTX 2.6M
- Earning Date
- TERN 11-10-2025
- MLTX 11-05-2025
- Dividend Yield
- TERN N/A
- MLTX N/A
- EPS Growth
- TERN N/A
- MLTX N/A
- EPS
- TERN N/A
- MLTX N/A
- Revenue
- TERN N/A
- MLTX N/A
- Revenue This Year
- TERN N/A
- MLTX N/A
- Revenue Next Year
- TERN N/A
- MLTX N/A
- P/E Ratio
- TERN N/A
- MLTX N/A
- Revenue Growth
- TERN N/A
- MLTX N/A
- 52 Week Low
- TERN $1.87
- MLTX $5.95
- 52 Week High
- TERN $21.12
- MLTX $62.75
- Technical
- Relative Strength Index (RSI)
- TERN 80.52
- MLTX 43.36
- Support Level
- TERN $7.87
- MLTX $9.84
- Resistance Level
- TERN $21.74
- MLTX $10.75
- Average True Range (ATR)
- TERN 1.46
- MLTX 0.63
- MACD
- TERN 1.11
- MLTX 1.49
- Stochastic Oscillator
- TERN 90.25
- MLTX 93.39
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.